FOLR1 and cancer: For example, Mirvetuximab soravtansine, a humanized FRα-targeting Ab conjugated with the maytansinoid DM4 drug, can induce cell-cycle arrest and cell death by targeting the microtubules of cancer cells (Kovtun et al., 2006; Lambert, 2013; Moore et al., 2018).